However, given that the response to PRMT5 inhibitor therapy is partially dependent on molecular contexts such as MTAP deletion or altered splicing as seen in glioblastoma, its mechanism may not be tissue-specific but molecularly defined. This evidence concerns the gene PRMT5 and glioblastoma.